SCHEMBL2140747

SCHEMBL2140747

CN(C)c1ccc(C(=O)OCC2COC(C)(C)O2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 1/20 0.46
ALDH1A1 P00352 7/20 0.45
HPGD P15428 4/20 0.45
MAPT P10636 4/20 0.45
NPC1 O15118 3/20 0.44
KDM4E B2RXH2 3/20 0.44
RAB9A P51151 3/20 0.44
HSD17B10 Q99714 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
GAA P10253 1/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
APP P05067 1/20 0.42
CA2 P00918 1/20 0.41
LMNA P02545 1/20 0.40
CYP3A4 P08684 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PRKCA P17252 1/20 0.40
PRKCE Q02156 1/20 0.40
RASGRP3 Q8IV61 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9739143 0.86 HTR7 (0.48) HTR7ALDH1A1HPGDMAPTNPC1
SCHEMBL23986033 0.85 LMNA (0.48) HTR7ALDH1A1HPGDMAPTNPC1
SCHEMBL6933031 0.84 ALDH1A1 (0.52) HTR7ALDH1A1NPC1GAAMAPK1
SCHEMBL9098184 0.84 ALDH1A1 (0.52) HTR7ALDH1A1NPC1GAAMAPK1
SCHEMBL2493185 0.84 ALDH1A1 (0.52) HTR7ALDH1A1NPC1GAAMAPK1
SCHEMBL17830008 0.84 HTR7 (0.47) HTR7ALDH1A1HPGDNPC1CA2
SCHEMBL19136746 0.82 KMT2A (0.49) HTR7ALDH1A1NPC1KDM4ESMN1; SMN2
SCHEMBL15542776 0.82 HTR7 (0.46) HTR7ALDH1A1HPGDHSD17B10CA2
SCHEMBL19321859 0.81 HTR7 (0.56) HTR7ALDH1A1HPGDMAPTRAB9A
SCHEMBL11684157 0.81 HTR7 (0.51) HTR7ALDH1A1NPC1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7863478-B2 1,3-Bis-[3-(4-methoxyphenyl)-2-propenoyloxy]-2-oxopropane; novel alpha-hydroxyketone derivatives as light-protection filters for cosmetic or drug products; used in cosmetic protective coatings; solar radiation; sunscreen agents; aging resistance; wrinkle resistance; food additives; dermatology MERCK PATENT GMBH (DE) 2011-01-04 US disclosed
US-7863478-B2 1,3-Bis-[3-(4-methoxyphenyl)-2-propenoyloxy]-2-oxopropane; novel alpha-hydroxyketone derivatives as light-protection filters for cosmetic or drug products; used in cosmetic protective coatings; solar radiation; sunscreen agents; aging resistance; wrinkle resistance; food additives; dermatology MERCK PATENT GMBH (DE) 2011-01-04 US disclosed
US-7863478-B2 1,3-Bis-[3-(4-methoxyphenyl)-2-propenoyloxy]-2-oxopropane; novel alpha-hydroxyketone derivatives as light-protection filters for cosmetic or drug products; used in cosmetic protective coatings; solar radiation; sunscreen agents; aging resistance; wrinkle resistance; food additives; dermatology MERCK PATENT GMBH (DE) 2011-01-04 US disclosed
US-20080038213-A1 Uv Filters MERCK PATENT GMBH (DE) 2008-02-14 US disclosed
US-20080038213-A1 Uv Filters MERCK PATENT GMBH (DE) 2008-02-14 US disclosed
US-20080038213-A1 Uv Filters MERCK PATENT GMBH (DE) 2008-02-14 US disclosed
EP-1776351-A1 UV FILTER MERCK PATENT GmbH (DE) 2007-04-25 EP disclosed
WO-2006018104-A1 UV FILTER MERCK PATENT GMBH (DE) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080038213-A1 Uv Filters ERCC4, ERCC1, ERCC5 HTR7 3774/4885ALDH1A1 334/4885HPGD 385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.